Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio shared long-term data at the ASH Annual Meeting on ZYNTEGLO® (betibeglogene autotemcel), a one-time gene therapy for beta-thalassemia patients requiring regular transfusions. Results from up to 10 years of follow-up show durable transfusion independence, improved hemoglobin levels, reduced iron burden, and sustained safety outcomes. Most participants achieved long-term benefits, including discontinuation of iron chelation therapy and enhanced quality of life. The therapy continues to demonstrate its potential to transform the management of severe genetic diseases.

Orca Bio Presents Clinical Results on Use of Orca-Q® without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting

Orca Bio presentó datos prometedores sobre Orca-Q, su terapia inmunológica alogénica de células T de segunda generación, en la 66.ª Reunión Anual de ASH. Este enfoque no requiere profilaxis contra la enfermedad injerto contra huésped (GvHD) en pacientes con donantes completamente compatibles y mostró bajas tasas de GvHD, infecciones y mortalidad no relacionada con recaídas. En un ensayo de Fase 1, los pacientes tratados con Orca-Q tuvieron una supervivencia libre de recaídas del 85%, alcanzando el 90% en un subgrupo con condiciones específicas. Orca-Q busca redefinir la terapia celular alogénica al eliminar la necesidad de inmunosupresores, preservando la seguridad y eficacia.

Chungbuk National University in South Korea introduces first quantum computer, IQM Spark

Chungbuk National University (CBNU) has announced the acquisition of its first quantum computer, the IQM Spark, from IQM Quantum Computers. This five-qubit full-stack system is the first commercial quantum computer installed in South Korea through a government procurement process and the second in the Asia-Pacific region. Installation is planned for early 2025, advancing quantum research, education, and industrial collaboration between Finland and Korea. The initiative is supported by CBNU's Chungbuk Quantum Research Center (CBQRC) and aligns with the South Korean government’s efforts to nurture quantum talent.

IHS Towers signs agreement to sell Kuwait operations to Zain Group

IHS Holding Limited (IHS Towers) has agreed to sell its 70% stake in IHS Kuwait Limited, comprising 1,675 sites and 700 managed sites, to Zain Group for an enterprise value of $230 million. The deal, part of IHS Towers' strategic review to improve its balance sheet, is expected to close in the first half of 2025, subject to regulatory approval. The transaction offers a significant premium to IHS Kuwait's valuation multiple, reflecting its strategic importance. Proceeds will be used to reduce IHS Towers' debt.

CUBI Investors Have Opportunity to Lead Customers Bancorp, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm reminds investors of a class action lawsuit against Customers Bancorp, Inc. (NYSE: CUBI) for alleged violations of the Securities Exchange Act of 1934. The lawsuit claims Customers Bancorp issued false and misleading statements regarding its anti-money laundering procedures and regulatory compliance, leading to investor damages. Shareholders who purchased securities between March 1, 2024, and August 8, 2024, have until January 31, 2025, to participate as lead plaintiffs.

Historic Anchor Room Bar & Grill Reopens in Hopewell, Virginia After Extensive Renovation

The historic Anchor Room Bar & Grill in Hopewell, Virginia, is reopening on November 29, 2024, after a significant renovation that preserves its 85-year legacy while introducing modern enhancements. Now under the ownership of Victoria and Eric Robinson and with renovations by Delta Citation, the space balances its historic charm with contemporary amenities. A Ribbon Cutting Ceremony will be held on December 12, 2024, at 2:00 PM, led by the Hopewell/Prince George Chamber of Commerce.

ATTENTION – CORRECTION: Here is the corrected dispatch: Altasciences supports Metsera in its preliminary clinical trials on obesity

Altasciences supported Metsera, Inc., in advancing its GLP-1 receptor agonist programs for obesity and metabolic diseases, including the successful Phase I/II trial of MET-097i, which demonstrated a 7.5% body weight reduction and a 380-hour half-life. Altasciences provided integrated drug development solutions, enabling Metsera to initiate a 16-week Phase II trial for MET-097i and clinical trials for additional candidates, MET-233i and MET-002.

Assent Achieve Award Winners Recognized for Supply Chain Sustainability Programs

Assent Inc. recognized manufacturing leaders at its Evolve 2024 conference for excellence in product compliance, ESG initiatives, and sustainability in supply chains. Awardees included Doosan Bobcat and Watts for compliance programs, Essex Furukawa for its ESG achievements, and Krisztina Strath of IMI for individual advocacy. The event highlighted innovative practices, regulatory updates, and Assent's sustainability initiatives, including donations to One Tree Planted.

Rosen Law Firm urges $JENNER investors who have suffered significant losses to contact the firm for information regarding their rights

The Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of the cryptocurrency $JENNER, alleging misleading business operations and investor communications. The complaint accuses defendant Caitlyn Jenner of making materially false and misleading statements regarding $JENNER's profitability, risks, financial health, and exchange listing, leading to investor losses once the truth emerged.

ASML Investors Have Opportunity to Lead ASML Holding N.V. Securities Fraud Lawsuit With the Schall Law Firm

The Schall Law Firm reminds investors of a class action lawsuit against ASML Holding NV (NASDAQ: ASML) for alleged violations of the Securities Exchange Act of 1934. The lawsuit alleges that ASML made false and misleading statements about problems in the semiconductor industry, sales recovery, and growth projections, resulting in losses to investors. The lawsuit covers the period from January 24, 2024, through October 15, 2024. Suspected investors have until January 13, 2025, to join the case.